UNIVERSITATIS UPSALIENSIS UPPSALA 2008 Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 335 Pharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Paliperidone for schizophrenia.

  2008cited by this paper
• Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.

  2008cited by this paper
• The Relationship Between the Response of Clinical Symptoms and Plasma Olanzapine Concentration, Based on Pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP)

  2008cited by this paper
• Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.

  2008influential reference
• 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity.

  2007cited by this paper
• -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.

  2007cited by this paper
• Paliperidone: quo vadis?

  2007cited by this paper
• A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

  2007cited by this paper
• Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

  2007cited by this paper
• Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.

  2007cited by this paper
• Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms

  2007cited by this paper
• Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

  2007cited by this paper
• Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis.

  2007cited by this paper
• Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

  2007cited by this paper
• BMC Medicine BioMed Central

  2007cited by this paper
• Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain.

  2006cited by this paper
• Risk Factors for Extrapyramidal Symptoms During Treatment With Selective Serotonin Reuptake Inhibitors, Including Cytochrome P-450 Enzyme, and Serotonin and Dopamine Transporter and Receptor Polymorphisms

  2006cited by this paper
• Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.

  2006cited by this paper
• The 5-HT2C receptor and antipsychoticinduced weight gain – mechanisms and genetics

  2006cited by this paper
• CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

  2006cited by this paper
• Risperidone-related Weight Gain: Genetic and Nongenetic Predictors

  2006cited by this paper
• Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.

  2006cited by this paper
• Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

  2005cited by this paper
• Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

  2005cited by this paper
• Weight change with atypical antipsychotics in the treatment of schizophrenia

  2005cited by this paper
• The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients

  2005cited by this paper
• Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.

  2005cited by this paper
• UDP-GLUCURONOSYLTRANSFERASE 1A4 POLYMORPHISMS IN A JAPANESE POPULATION AND KINETICS OF CLOZAPINE GLUCURONIDATION

  2005cited by this paper
• Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.

  2005cited by this paper
• Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005influential reference
• Modulation of dopamine release by striatal 5‐HT2C receptors

  2005cited by this paper
• Complex HTR2C linkage disequilibrium and promoter associations with body mass index and serum leptin

  2005cited by this paper
• Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

  2005cited by this paper
• Metabolic Syndrome and Cardiovascular Disease

  2005cited by this paper
• The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity.

  2004cited by this paper
• Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism

  2004cited by this paper
• Continuing clozapine treatment despite neutropenia

  2004cited by this paper
• His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation.

  2004cited by this paper
• Modification of human 5-HT2C receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution

  2004cited by this paper
• Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

  2004cited by this paper
• Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.

  2004cited by this paper
• Pharmacogenetics of antipsychotic-induced weight gain

  2004cited by this paper
• Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

  2004cited by this paper
• Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro.

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia.

  2004cited by this paper
• Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity: Clinical Data and Analysis of CYP1A2 Gene

  2004cited by this paper
• Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses

  2003cited by this paper
• Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.

  2003influential reference
• Digoxin pharmacokinetics and MDR1 genetic polymorphisms

  2003influential reference
• New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

  2003cited by this paper
• Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

  2003cited by this paper
• MDR1 Genotype-Related Duodenal Absorption Rate of Digoxin in Healthy Japanese Subjects

  2003influential reference
• Metabolic drug interactions with new psychotropic agents

  2003cited by this paper
• Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.

  2003cited by this paper
• CYP3A5 variant allele frequencies in Dutch Caucasians.

  2002cited by this paper
• Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

  2002cited by this paper
• Glucuronidation of olanzapine by cDNA‐expressed human UDP‐glucuronosyltransferases and human liver microsomes

  2002cited by this paper
• The effects of novel antipsychotics on glucose and lipid levels.

  2002cited by this paper
• The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment

  2002cited by this paper
• The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and −141C Ins/Del polymorphisms

  2002cited by this paper
• In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

  2002cited by this paper
• Significant Genetic Linkage of MDR1 Polymorphisms at Positions 3435 and 2677: Functional Relevance to Pharmacokinetics of Digoxin

  2002cited by this paper
• Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene

  2002cited by this paper
• Glucose Intolerance with Atypical Antipsychotics

  2002cited by this paper
• Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics

  2002influential reference
• General Summary

  2002cited by this paper
• Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

  2002cited by this paper
• Cytochrome P450 polymorphisms and response to antipsychotic therapy.

  2002influential reference
• Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.

  2002cited by this paper
• Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine

  2001cited by this paper
• Different effects of antipsychotic drugs on insulin release in vitro.

  2001cited by this paper
• Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

  2001cited by this paper
• Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.

  2001cited by this paper
• Contributions of Five Human Cytochrome P450 Isoforms to the N‐demethylation of Clozapine In Vitro at Low and High Concentrations

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001influential reference
• Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.

  2001influential reference
• Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.

  2001influential reference
• The CYP3A4*3 allele: is it really rare?

  2001influential reference
• CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.

  2000influential reference
• Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

  2000cited by this paper
• Pharmacogenetic prediction of clozapine response.

  2000cited by this paper
• Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.

  2000cited by this paper
• Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action.

  2000cited by this paper
• Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000influential reference
• Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder

  2000cited by this paper
• Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.

  2000influential reference
• P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

  2000cited by this paper
• Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility

  2000cited by this paper
• Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS.

  2000cited by this paper
• CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

  2000cited by this paper
• Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection.

  2000cited by this paper
• Pharmacologic profile of perphenazine's metabolites.

  2000cited by this paper
• Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and Type II diabetes

  2000cited by this paper
• Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.

  1999cited by this paper
• Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers

  1999cited by this paper
• Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

  1999influential reference
• Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.

  1999cited by this paper

• No citing papers are available for this paper.